开云app官网登录入口网页版-官方正版

#Alectinib#

6篇内容 | 877人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1947288, encodeId=70e9194e28846, content=<a href='/topic/show?id=9c23228e32' target=_blank style='color:#2F92EE;'>#Alectinib#</a>, objectTitle=WCLC 2019：Alectinib治疗克唑替尼耐药性的ALK+ NSCLC, objectType=article, longId=179242, objectId=f5951e9242cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5951e9242cd, replyNumber=0, likeNumber=66, createdTime=2020-01-26, rootId=0, userName=12498b08m90暂无昵称, userId=9d0b2500136, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5951e9242cd, moduleTitle=WCLC 2019：Alectinib治疗克唑替尼耐药性的ALK+ NSCLC, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f5951e9242cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947287, encodeId=95ee194e2877c, content=<a href='/topic/show?id=9c23228e32' target=_blank style='color:#2F92EE;'>#Alectinib#</a>, objectTitle=NEJM：未经治疗的ALK阳性非小细胞肺癌患者采用Alectinib和Crizotinib治疗的疗效比较！, objectType=article, longId=101153, objectId=1b50101153e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b50101153e0, replyNumber=0, likeNumber=73, createdTime=2018-05-09, rootId=0, userName=12498b08m90暂无昵称, userId=9d0b2500136, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b50101153e0, moduleTitle=NEJM：未经治疗的ALK阳性非小细胞肺癌患者采用Alectinib和Crizotinib治疗的疗效比较！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1b50101153e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947286, encodeId=2e31194e286d0, content=<a href='/topic/show?id=9c23228e32' target=_blank style='color:#2F92EE;'>#Alectinib#</a>, objectTitle=ALK阳性NSCLC治疗药物Aalectinib被FDA授予突破性药物资格, objectType=article, longId=79315, objectId=590ee9315c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=590ee9315c5, replyNumber=0, likeNumber=74, createdTime=2017-06-26, rootId=0, userName=12498b08m90暂无昵称, userId=9d0b2500136, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=590ee9315c5, moduleTitle=ALK阳性NSCLC治疗药物Aalectinib被FDA授予突破性药物资格, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=590ee9315c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947285, encodeId=a706194e28589, content=<a href='/topic/show?id=9c23228e32' target=_blank style='color:#2F92EE;'>#Alectinib#</a>, objectTitle=患者招募：一项比较ALECTINIB与克唑替尼用于治疗初治的ALK阳性晚期非小细胞肺癌的随机、多中心、III期、开放性研究, objectType=article, longId=61213, objectId=718a6121359, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=718a6121359, replyNumber=0, likeNumber=56, createdTime=2016-06-14, rootId=0, userName=12498b08m90暂无昵称, userId=9d0b2500136, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=718a6121359, moduleTitle=患者招募：一项比较ALECTINIB与克唑替尼用于治疗初治的ALK阳性晚期非小细胞肺癌的随机、多中心、III期、开放性研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=718a6121359)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947284, encodeId=e1ea194e2844b, content=<a href='/topic/show?id=9c23228e32' target=_blank style='color:#2F92EE;'>#Alectinib#</a>, objectTitle=Lancet Oncol：Alectinib治疗ALK阳性，克唑替尼耐药，非小细胞肺癌患者疗效显著, objectType=article, longId=60861, objectId=be8c6086141, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be8c6086141, replyNumber=0, likeNumber=85, createdTime=2016-07-17, rootId=0, userName=12498b08m90暂无昵称, userId=9d0b2500136, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be8c6086141, moduleTitle=Lancet Oncol：Alectinib治疗ALK阳性，克唑替尼耐药，非小细胞肺癌患者疗效显著, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=be8c6086141)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947283, encodeId=35cc194e283e7, content=<a href='/topic/show?id=9c23228e32' target=_blank style='color:#2F92EE;'>#Alectinib#</a>, objectTitle=JTO：Alectinib能用于ALK阳性的耐药的非小细胞肺癌脑转移治疗, objectType=article, longId=46481, objectId=83624648114, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83624648114, replyNumber=0, likeNumber=72, createdTime=2015-03-11, rootId=0, userName=12498b08m90暂无昵称, userId=9d0b2500136, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83624648114, moduleTitle=JTO：Alectinib能用于ALK阳性的耐药的非小细胞肺癌脑转移治疗, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=83624648114)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

Alectinib

2020-05-29

12498b08m90暂无昵称 (审核中...)

前往app查看评论内容

#Alectinib#

WCLC 2019：Alectinib治疗克唑替尼耐药性的ALK+ NSCLC

2020-01-26

12498b08m90暂无昵称 (审核中...)

前往app查看评论内容

#Alectinib#

NEJM：未经治疗的ALK阳性非小细胞肺癌患者采用Alectinib和Crizotinib治疗的疗效比较！

2018-05-09

12498b08m90暂无昵称 (审核中...)

前往app查看评论内容

#Alectinib#

ALK阳性NSCLC治疗药物Aalectinib被FDA授予突破性药物资格

2017-06-26

12498b08m90暂无昵称 (审核中...)

前往app查看评论内容

#Alectinib#

患者招募：一项比较ALECTINIB与克唑替尼用于治疗初治的ALK阳性晚期非小细胞肺癌的随机、多中心、III期、开放性研究

2016-06-14

12498b08m90暂无昵称 (审核中...)

前往app查看评论内容

#Alectinib#

Lancet Oncol：Alectinib治疗ALK阳性，克唑替尼耐药，非小细胞肺癌患者疗效显著

2016-07-17

12498b08m90暂无昵称 (审核中...)

前往app查看评论内容

#Alectinib#

JTO：Alectinib能用于ALK阳性的耐药的非小细胞肺癌脑转移治疗

2015-03-11

科室
- - 订阅+
  - 更多科室
工具
服务